Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: The potential role for regulatory T cells

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 29-33

  Tu, Haiyan ^a,b,c   Li, Qi ^a,b   Xiang, Shilong ^a,b   Jiang, Hong ^a,b   Mao, Youying ^a,b   Shou, Zhangfei ^a,b   Chen, Jianghua ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Regulatory T cells; SLE related atherosclerosis; Statins; Systemic lupus erythematosus

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CELL EXPANSION; CLINICAL FEATURE; CLINICAL PROTOCOL; DISEASE EXACERBATION; DRUG EFFECT; ELECTRON BEAM TOMOGRAPHY; HYPOTHESIS; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES, REGULATORY;

EID: 84862823811     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.023     Document Type: Article

References (56)

1. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8:457-462.
2. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
3. Mallat Z., Ait-Oufella H., Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 2005, 16:518-524.
4. Bessant R., Hingorani A., Patel L., et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43:924-929.
5. Bonelli M., Savitskaya A., von Dalwigk K., et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008, 20:861-868.
6. Crispin J.C., Martinez A., Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003, 21:273-276.
7. Mellor-Pita S., Citores M.J., Castejon R., et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis 2006, 65:553-554.
8. Valencia X., Yarboro C., Illei G., et al. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
9. Lee J.H., Wang L.C., Lin Y.T., et al. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006, 117:280-286.
10. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
11. Mor A., Planer D., Luboshits G., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:893-900.
12. Mor A., Luboshits G., Planer D., et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J 2006, 27:2530-2537.
13. de Boer O.J., van der Meer J.J., Teeling P., et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One 2007, 2:e779.
14. Kwak B., Mulhaupt F., Myit S., et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
15. Riboldi P., Gerosa M., Meroni P.L. Statins and autoimmune diseases. Lupus 2005, 14:765-768.
16. Tang T.T., Song Y., Ding Y.J., et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 2011, 52:1023-1032.
17. Paraskevas K.I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008, 27:281-287.
18. Lawman S., Mauri C., Jury E.C., et al. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 2004, 173:7641-7646.
19. Abud-Mendoza C., de la Fuente H., Cuevas-Orta E., et al. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003, 12:607-611.
20. Ferreira G.A., Navarro T.P., Telles R.W., et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 2007, 46:1560-1565.
21. Kotyla P.J., Sliwinska-Kotyla B., Kucharz E.J. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol 2006, 33:2361-2363. [author reply 2363].
22. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
23. Fathy A., Mohamed R.W., Tawfik G.A., et al. Diminished CD4+CD25+ T-lymphocytes in peripheral blood of patients with systemic lupus erythematosus. Egypt J Immunol 2005, 12:25-31.
24. Lyssuk E.Y., Torgashina A.V., Soloviev S.K., et al. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007, 601:113-119.
25. Vargas-Rojas M.I., Crispin J.C., Richaud-Patin Y., et al. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008, 17:289-294.
26. Zhang B., Zhang X., Tang F., et al. Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol 2008, 153:182-187.
27. Suen J.L., Li H.T., Jong Y.J., et al. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009, 127:196-205.
28. Barreto M., Ferreira R.C., Lourenco L., et al. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol 2009, 10:5.
29. Barath S., Soltesz P., Kiss E., et al. The severity of systemic lupus erythematosus negatively correlates with the increasing number of CD4+CD25(high)FoxP3+ regulatory T cells during repeated plasmapheresis treatments of patients. Autoimmunity 2007, 40:521-528.
30. Miyara M., Amoura Z., Parizot C., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005, 175:8392-8400.
31. Franz B., Fritzsching B., Riehl A., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007, 56:1910-1920.
32. Kagami S., Owada T., Kanari H., et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol 2009, 21:679-689.
33. Mira E., Leon B., Barber D.F., et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol 2008, 181:3524-3534.
34. Mausner-Fainberg K., Luboshits G., Mor A., et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008, 197:829-839.
35. Kim Y.C., Kim K.K., Shevach E.M. Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology 2010, 130:484-493.
36. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
37. Soubrier M., Mathieu S., Dubost J.J. Atheroma and systemic lupus erythematosus. Joint Bone Spine 2007, 74:566-570.
38. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
39. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
40. Matsuura E., Kobayashi K., Lopez L.R. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 2008, 7:214-222.
41. McMahon M., Hahn B.H., Skaggs B.J. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol 2011, 7:227-241.
42. Shoenfeld Y., Sherer Y., Harats D. Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001, 22:293-295.
43. Yang K., Li D., Luo M., et al. Generation of HSP60-specific regulatory T cell and effect on atherosclerosis. Cell Immunol 2006, 243:90-95.
44. Harats D., Yacov N., Gilburd B., et al. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002, 40:1333-1338.
45. Hu Z., Li D., Hu Y., et al. Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin. J Huazhong Univ Sci Technol Med Sci 2007, 27:524-527.
46. Aprahamian T., Bonegio R., Rizzo J., et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006, 177:3028-3034.
47. Mok C.C., Wong C.K., To C.H., et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2011, 63:875-883.
48. Plazak W., Gryga K., Dziedzic H., et al. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011, 13:R117.
49. Tiemessen M.M, Jagger A.L., Evans H.G., et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007, 104:19446-19451.
50. Maloy K.J., Salaun L., Cahill R., et al. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003, 197:111-119.
51. Lin J., Li M., Wang Z., et al. The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res 2010, 51:1208-1217.
52. Li M., Lin J., Wang Z., et al. Oxidized low-density lipoprotein-induced proinflammatory cytokine response in macrophages are suppressed by CD4CD25(+)Foxp3(+) regulatory T cells through downregulating toll like receptor 2-mediated activation of NF-kappaB. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2010, 25:649-656.
53. Andre S., Tough D.F., Lacroix-Desmazes S., et al. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 2009, 174:1575-1587.
54. O'Neill S.G., Giles I., Lambrianides A., et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62:845-854.
55. Delgado Alves J., Kumar S., Isenberg D.A. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003, 42:893-899.
56. Narshi C.B., Giles I.P., Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus 2011, 20:5-13.